Melinta Therapeutics Inc. buy marge

marge stimmt dem augenblicklichen Sentiment von 'Sell' nicht zu

Importantly, the FDA did not order the removal of telithromycin from the
market after these adverse events - it merely restricted it's approved
uses because the risk/benefit profile no longer justified all of the
initially approved uses. Critically, it remains approved for CABP of
mild to moderate severity, which is promising for the outlook of
solithromycin approval for the same indication. Also, solithromycin has a
big edge due to its superior performance against resistant bacteria. I
don't think the FDA can afford not to approve it, given the growing
crisis in antibacterial resistance, and the dwindling treatment options
out there.